### **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2022

#### **Prelude Therapeutics Incorporated** (Exact name of registrant as specified in its charter)

Delaware te or other jurisdiction of incorporation) (State

001-39527 (Commission File Number)

81-1384762 (IRS Employer Identification No.)

200 Powder Mill Road Wilmington, Delaware, 19803 (Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (302) 467-1280

N/A (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, \$0.0001 par value	PRLD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

#### Item 7.01. Regulation FD Disclosure

Prelude Therapeutics Incorporated (the "Company") has prepared investor presentation materials with information about the Company, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished with this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01	Financial Statements and Exhibits	
(d) Exhibits		
Exhibit No.	Description	
99.1	Presentation	
104	Cover Page Interactive Data File (embedded within the Inline XBRL Document)	

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 10, 2022

#### PRELUDE THERAPEUTICS INCORPORATED

By: /s/ Laurent Chardonnet Laurent Chardonnet Chief Financial Officer



# Precision Oncology Redefined

Corporate Presentation January 2022


# **Forward Looking Statements**

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: our plans to develop and commercialize small molecule therapies, our expectations about timing and ability to commence, enroll or complete clinical studies and to obtain regulatory approvals for PRT543, PRT811, PRT1419, PRT2527 and other candidates in development, the ability of our product candidates to treat various cancers, the ability to discover additional suitable candidates for regulatory approval, the potential impact of the COVID-19 pandemic and the sufficiency of our cash and cash equivalents to fund our operations.

Any statements contained herein or provided orally that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "plan," "expect" and similar expressions that convey uncertainty of future events or outcomes, although not all forward-looking statements contain these words. Statements, including forward-looking statements, speak only to the date they are provided (unless an earlier date is indicated).

These forward-looking statements are based on the beliefs of our management as well as assumptions made by and information currently available to us. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. If such assumptions do not fully materialize or prove incorrect, the events or circumstances referred to in the forward-looking statements may not occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations, except as required by law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Additional risks and uncertainties that could affect our business are included under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the three months ended September 30, 2021.






Build a fully integrated oncology company on the foundation of drug discovery excellence to deliver novel precision oncology medicines to patients with underserved cancers



# **Prelude Therapeutics: Building for Success**

## Internal Discovery Engine

Powered by experienced drug developers with a *proven track record* of multiple successful oncology medicines



### **Differentiated R&D Approach**

Effective *integration* between cancer biology and medicinal chemistry to rapidly iterate and discover optimized molecules in a target class agnostic fashion

### Strong Execution and Commitment to Discovery

4 INDs approved in 4 years; 4 *differentiated* clinical candidates currently advancing through Phase 1 and into Phase 2/3 clinical development; 2 new additional INDs expected in 2022

### **Focused Clinical Development in Underserved Cancers**

Clinical trial designs in selected cancer patients allowing *efficient 'go / no go' decisions* in caner types *with* potential for *rapid regulatory approval* 

## Strong Financial Position: ~\$320M Cash & Marketable Securities (9/30/21)



# Building a Deep Portfolio of Oncology Assets

Target	PRMT5	MCL1	CDK9	SMARCA2 (BRM)
MOA	mRNA Splicing & DNA Repair	Apoptosis	Transcriptional Regulation	Synthetic Lethality
Molecule(s)	PRT543 & PRT811	PRT1419	PRT2527	PRT-SCA2
Development Stage	Phase 1 Expansion	Phase 1 Escalation	Phase 1 Escalation	IND Target 2022
Target Cancers	Spliceosome Mutations Selected CNS HRD+	Venetoclax and TKI- Resistant Heme and Solid	MYC-driven Heme and Solid	SMARCA4 (BRG1) Deleted NSCLC and Others
		1	1	5


# **Diversified Precision Oncology Pipeline**

Program	Cancer Indications	IND Enabling	Phase 1 Escalation	Phase 1 Expansion	Phase 2/3	Upcoming Milestones
PRT543 (PRMT5)	ACC, HRD+, spliceosome mutations —			-•		
	Selected myeloid malignancies (incl. MF and MDS) —			-•		Data readouts 2H22
PRT811 (Brain Penetrant PRMT5)	IDH+ high grade glioma, uveal melanoma			-•		Data readouts 2H22
PRT1419 (MCL1)	Selected hematological malignancies and solid tumors		-•			Dose escalation data readout 2H22
PRT2527 (CDK9)	Selected solid and hematological		-•			Dose escalation data YE 2022
PRT-SCA2 (SMARCA2)	Multiple genomically	•				IND filing target 2022
PRT-K4 (Kinase)	Solid tumors -	•				IND filing target 2022

S Prelude


# 2021 Accomplishments and 2022 Goals

	2021	DDWT		2022	
$\checkmark$	<ul> <li>PRT543</li> <li>Identified RP2D</li> <li>Demonstrated favorable safety profile and preliminary clinical activity</li> <li>Multiple expansions initiated</li> <li>PRT811</li> <li>Identified RP2D</li> <li>Best-in-class potential demonstrated; Expansion phase initiated</li> </ul>	PRMT5	• D	iomplete expansion phases for both molecules lemonstrate PoC in one or more indications dvance PRMT5 program into Phase 2	
$\checkmark$	<ul> <li>Phase 1 dose escalation with oral formulation ongoing</li> <li>Phase 1 dose escalation with IV formulation initiated</li> </ul>	MCL1	• De	stablish RP2D emonstrate safety in combination with Venetoclax/Azacitidine emonstrate PoC	
$\checkmark$	<ul><li>Successfully filed IND</li><li>Phase 1 Initiated</li></ul>	CDK9		omplete dose escalation stablish safety, target engagement and RP2D	]
$\checkmark$	<ul> <li>PRT-SCA2 - IND Enabling Studies Initiated; IND target in 2022</li> <li>PRT-K4 - IND Enabling Studies Initiated; IND target in 2022</li> </ul>	Preclinica	• F	ile INDs nitiate Phase 1 studies	
	Therapeutics	K	4	XIII	7



# **PRMT5** Pathway Drives Oncogenesis and Resistance

- PRMT5 catalyzes symmetric arginine dimethylation (sDMA) of protein substrates including histones, transcription factors, and spliceosome proteins
- Dimethylated substrates of PRMT5 control key oncogenic and resistance mechanisms
- PRMT5 inhibition is highly efficacious in models with mutations in DNA repair or mRNA splicing pathways in preclinical models
- PRMT5 inhibition can be leveraged to target genetically selected patient populations in the clinic



S Prelude

# PRT543 PRT811

Potential Best-In-Class PRMT5 Inhibitors





### **Differentiated PRMT5 Inhibitors**

- · Highly selective and potent oral candidates
- PRT811 is highly differentiated in the class with high brain penetration potential

# Applicability in Both Solid Tumors and Heme

- Strong scientific rationale and robust preclinical activity across broad range of cancers
- · Early clinical signals in multiple cancer types



### **Optimized PK Profile**


- High oral bioavailability and optimal half-life to maximize therapeutic window
- Differentiated safety and clinical activity profile




### Potential Rapid Path to Market

- · Potential for accelerated approval pathway
- Opportunity in multiple cancer types

# **PRMT5: Phase 1 Overview**



# PRT543 and PRT811 Demonstrate Desirable PK and PD Properties



# PRMT5 - Phase 1 Dose Escalation: Safety and Clinical Activity\*

### **PRT543**

### Study Demographics & Safety

- Unselected patient population with advanced solid tumors and myeloid malignancies
   Safety
- Most common Grade ≥ 3 AEs were thrombocytopenia and anemia
- · Thrombocytopenia is the only DLT
- Reversible upon dose modification
- Low incidence (<20%) at expansion doses

#### **Preliminary Clinical Activity**

- Durable CR in a patient with HRD+ ovarian cancer (35 mg 5x/wk; still on Rx)
- Stable disease and tumor regressions (<30%) in 5 patients including ACC and uveal melanoma
- Sustained hemoglobin and anemia improvements in multiple patients with myeloid malignancies

# 23 Prelude

### **PRT811**

#### Study Demographics & Safety

- Unselected patient population with advanced cancers including GBM Safety
- Grade ≥ 3 AEs were uncommon (occurring in 11% of patients)
- · No DLTs up to 600 mg QD

#### **Preliminary Clinical Activity**

- One patient with IDH1 mutated GBM experienced durable
   PR that evolved into CR (still on Rx)
- Two splicing mutated uveal melanoma patients demonstrated anti-tumor activity including a uPR and a 25% tumor regression

\*Data presented at 2021 AACR-NCI-EORTC and ASH Annual Meetings

# **PRMT5** Phase 1: Key Takeaways and Next Steps

## Favorable Safety Profile

- PRT543 and PRT811
   well tolerated
- Favorable safety
   properties
- Low incidence of doselimiting toxicities at expansion doses

### Desirable PK & PD Profiles

- Dose-dependent
   increase in exposure
- High levels of target inhibition
- PRT811 demonstrated best-in-class profile with wide therapeutic window


### Preliminary Clinical Activity

- Objective responses in solid tumors
- IWG anemia benefit in myeloid malignancies
- Anti-tumor activity observed in relapsed/refractory patients with target biomarker profile


### **Next Steps**

- Dose expansion ongoing
- Data readouts from multiple cohorts in 2022
- Prioritize indications for advancement into P2

# S Prelude



# **MCL1: Targeting Cancer Cell Survival**



- MCL1 is a member of family inhibitors of apoptosis (BCL2); often overexpressed in cancers
- BCL2 family is clinically validated Venetoclax approved for lymphoid and myeloid malignacies
- MCL-1 is a bypass and resistance mechanism for venetoclax and multiple TKIs
- Challenging medicinal chemistry target that requires disruption of protein-protein interaction

Prelude THERAPEUTICS

## PRT1419

Differentiated Clinical-Stage MCL1 Inhibitor Candidate

Prelude

# 22

# 문고

### MCL1 Inhibitor

- Potent and selective
- No cardiotoxicity signal in GLP-toxicology Studies

### **Targeting Selected Heme and Solid Cancers**

- Robust activity in preclinical models with once weekly dosing
- Potential combination strategy with Venetoclax and/or HMAs in Hematological malignancies


### Optimized PK Profile Maximizes Therapeutic Window


- Higher clearance built in to achieve desirable duration of target inhibition
- Optimal physicochemical properties

### Potential Rapid Path to Market


 Venetoclax-resistant cancers offer opportunity for accelerated approval







# **CDK9: Targeting Cancer Through Transcriptional Regulation**



- CDK9 phosphorylates RNA Pol II and regulates transcription
- Regulates expression of several immediate early genes driving oncogenesis and resistance (i.e. MYC, MYB, MCL1)
- Non-selective CDK9 inhibitors have demonstrated clinical activity in multiple tumor types but poor tolerability
  - Lack of selectivity and potency vs other CDK9s is believed to contribute to low therapeutic window

23 Prelude

# PRT2527

# Potential Best-in-Class Selectivity and Potency

Prelude


## **CDK9** Inhibitor


- Most selective in the class vs CDK family and across the kinome
- Low nanomolar potency in blocking tumor cell proliferation

# 명화

### **Targeting Selected Heme and Solid Cancers**


- · Robust activity in preclinical models at well-tolerated doses
- Enhanced sensitivity in tumors that are MYC-dependent
- · Provides patient selection strategy in clinic








# Targeting SMARCA2 (BRM): Leveraging Synthetic Lethality



S Prelude

- The chromatin remodeling (SWI/SNF) complex is frequently mutated in cancer making it a potential therapeutic target
- Activity of the SWI/SNF complex requires either SMARCA4 (BRG1) or SMARCA2 (BRM)
- Loss of SMARCA4 (BRG1) through mutation leads to dependency on SMARCA2 (BRM)
- Subsets of solid tumors express SMARCA4 (BRG1) mutations
- Selectively inhibiting SMARCA2 (BRM) offers an attractive approach to target SMARCA4 (BRG1) mutant tumors

# Achieving SMARCA2 Selectivity Through Degrader Approach




Mullard A. Nat Rev Drug Discov. 2019

- SMARCA2 selectivity over highly homologous SMARCA4 isoform has been a challenging medicinal chemistry problem with traditional small molecule approaches
- Targeted Protein Degradation (TPD) of SMARCA2 selectively over SMARCA4 is possible through differences in ternary complexes
- Prelude scientists identified the molecular basis for achieving high degree of selectivity for SMARCA2 over SMARCA4
- Lead molecules from multiple chemical scaffolds with subnanomolar potency and selectivity have been discovered





# PRT-SCA2: Potent and Selective SMARCA2 Degrader with in Vivo Activity





# SMARCA2 Degrader Program Overview







- Internal discovery engine
- Differentiated R&D approach
- Strong execution and commitment to discovery
- Focused clinical development in underserved cancers
- Strong financial position: ~\$320M cash and marketable securities at 9/30/21

